pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Evenity
drug · antibody
save

romosozumab

Phase 3updated 3mo ago
by $AMGN AMGEN INC🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 2
  • company$AMGNAMGEN INC2 co-mentions · 1 sources
  • tagRecall2 co-mentions · 1 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Sclerostin

all catalysts(0)

nothing on the calendar yet

Trials studying romosozumab

  • phase2Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCIactive not recruitingn=36
  • phase3Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfectarecruitingn=106
  • phase2Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomesnot yet recruitingn=36
  • phase2Romosozumab/Denosumab Study for Premenopausal IOPactive not recruitingn=30
  • phase1Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjectsenrolling by invitationn=118
  • phase3Effects of Romosozumab on Bone Density in Women With Anorexia Nervosacompletedn=30
  • phase4A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.completedn=100
  • phase2Romosozumab in Women With Chronic SCIcompletedn=12
more trials →

News(0)

no news has mentioned this drug yet

brand
Evenity
trade names
Evenity
generic
romosozumab-aqqg
MOA
Sclerostin inhibitor
indication
Osteogenesis Imperfecta
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 27m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?